UL Earnings

UL reported its FY2029Q1 earnings on 2025-07-31, showcasing a revenue of 15.00B against an estimate of 16.00B, resulting in a -1.53% surprise. The EPS was 0, surpassing the expected 0 by 0% . The stock experienced a -0.98% price change on the earnings day and a 1.9% change over the next five days, reflecting market reactions to the results.

Following UL's FY2029Q1 earnings announcement on 2025-07-31, the stock price moved by -0.98% on the day of the release. Over the subsequent five days, it saw a 1.90% change. Historically, UL's stock price tends to shift by an average of +0.79% in the 10 days leading up to earnings and +3.55% in the 10 days following, providing insight into potential market.

For , analysts estimate UL’s annual revenue to reach undefined, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -14.25% and EPS estimates Revise Downward by -8.78% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between UL's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -14.25%, while EPS estimates moved Revise Downward by -8.78% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, UL's stock price typically moves by +0.79% in the 10 days before its earnings and +3.55% in the 10 days after. For the upcoming earnings, analysts expect an EPS of undefined and revenue of undefined.

The earnings call presents mixed signals. Positive aspects include a strong cash position, new partnerships, and growth in U.S. Vascular Access. However, declining gross margins, a decrease in EBITDA, and uncertainties in the U.S. Advanced Wound Care channel weigh negatively. The Q&A section highlights management's optimism and strategic plans but lacks clarity on key issues. Given these mixed factors, the stock price is likely to remain stable over the next two weeks, resulting in a neutral sentiment prediction.